GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medivir AB (OTCPK:MVRBY) » Definitions » Additional Paid-In Capital

Medivir AB (Medivir AB) Additional Paid-In Capital : $0.00 Mil(As of Mar. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Medivir AB Additional Paid-In Capital?


Medivir AB's quarterly additional paid-in capital increased from Sep. 2023 ($72.68 Mil) to Dec. 2023 ($88.74 Mil) but then stayed the same from Dec. 2023 ($88.74 Mil) to Mar. 2024 ($0.00 Mil).

Medivir AB's annual additional paid-in capital declined from Dec. 2021 ($88.56 Mil) to Dec. 2022 ($77.60 Mil) but then increased from Dec. 2022 ($77.60 Mil) to Dec. 2023 ($88.74 Mil).

Medivir AB Additional Paid-In Capital Historical Data

The historical data trend for Medivir AB's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medivir AB Additional Paid-In Capital Chart

Medivir AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 44.55 50.32 88.56 77.60 88.74

Medivir AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 76.87 74.81 72.68 88.74 -

Medivir AB Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Medivir AB Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Medivir AB's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Medivir AB (Medivir AB) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medivir AB (OTCPK:MVRBY) » Definitions » Additional Paid-In Capital
Comparable Companies
OSTO:SYNACT OSTO:ACE XSAT:HAMLET B XSAT:CURAS OSTO:IVACC OSTO:MAGLE OSTO:CLBIO OSTO:NICA OSTO:IMMU OSTO:SANION OCSE:NOVO B VRTX REGN ASX:CSL XKRX:207940 MRNA XKRX:068270 XBRU:ARGX XBRU:UCB BNTX
Traded in Other Exchanges
MVIR:Sweden MVR0:Germany MVR0:Germany
Address
Lunastigen 5, PO Box 1086, 2nd floor, Huddinge, SWE, 141 22
Website
https://www.medivir.com
Medivir AB develops drugs with a focus on cancers where there are medical needs. The company invests in indication areas where available treatment methods are limited or lacking and there are opportunities to offer significant improvements to patients. Medivir focuses on the development of MIV-818, a prodrug that has been designed to provide a targeted anti-tumor effect in the liver while minimizing any side effects. Birinapant, a SMAC mimetic, has been out-licensed for development in combination with IGM antibodies for the treatment of solid tumors.